Q-omics provides the consensus-scored GAPDHP14 profile across patient tissues and cancer cell-line models. GAPDHP14 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GAPDHP14 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, GAPDHP14 RNA expression shows 11,097 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, HNSC, and TGCT as cancer lineages where GAPDHP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP14 survival associations across molecular data types. GAPDHP14 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP14 RNA expression–survival associations across cancer types. High GAPDHP14 expression shows unfavorable associations in BRCA, ACC, KIRC, LGG and THCA, but favorable associations in SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for GAPDHP14 RNA expression.
This table summarizes GAPDHP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP14 shows higher tumor expression in HNSC, KIRC, STAD, COAD, LIHC and PRAD. The HNSC box plot shows higher GAPDHP14 RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p = .002).
This table shows molecular features associated with GAPDHP14 in patient tissues and cancer cell lines. In patient samples, GAPDHP14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
